Hani Boshra

Dr. Hani Boshra

Global Urgent and Advanced Research and Development (GUARD), Batiscan, QC, Canada
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2006 in Fish & Shellfish Immunology
Verified
Journal Article
Closed access
HBHani Boshra
Hani Boshra
JLJ. Li
J. Li
JSJ.O. Sunyer
J.O. Sunyer

17 September 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
JLJun Li
Jun Li
DBDaniel Barreda
Daniel Barreda
YZYona-An Zhang
Yona-An Zhang
HBHani Boshra
Hani Boshra
AGAndrew E Gelman
Andrew E Gelman
JSJ Oriol Sunyer
J Oriol Sunyer

1 July 2011 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
HBHani Boshra
Hani Boshra
GLGema Lorenzo
Gema Lorenzo
NBNúria Busquets
Núria Busquets
ABAlejandro Brun
Alejandro Brun
Rift Valley fever virus (RVFV) is a zoonotic pathogen that primarily affects ruminants but can also be lethal in humans. A negative-stranded RNA virus of the familyBunyaviridae, this pathogen is transmitted mainly via mosquito vectors. RVFV has shown the ability to inflict significant damage to livestock and is also a threat to public health. While outbreaks have traditionally occurred in sub-Saharan Africa, recent outbreaks in the Middle East have raised awareness of the potential of this virus to spread to Europe, Asia, and the Americas. Although the virus was initially characterized almost 80 years ago, the only vaccine approved for widespread veterinary use is an attenuated strain that has been associated with significant pathogenic side effects. However, increased understanding of the molecular biology of the virus over the last few years has led to recent advances in vaccine design and has enabled the development of more-potent prophylactic measures to combat infection. In this review, we discuss several aspects of RVFV, with particular emphasis on the molecular components of the virus and their respective roles in pathogenesis and an overview of current vaccine candidates. Progress in understanding the epidemiology of Rift Valley fever has also enabled prediction of potential outbreaks well in advance, thus providing another tool to combat the physical and economic impact of this disease.

30 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TTThang Truong
Thang Truong
HBHani Boshra
Hani Boshra
CECarissa Embury-Hyatt
Carissa Embury-Hyatt
CNCharles Nfon
Charles Nfon
VGVolker Gerdts
Volker Gerdts
SBShawn Babiuk
Shawn Babiuk
Peste des petits ruminants (PPR) is a viral disease which primarily affects small ruminants, causing significant economic losses for the livestock industry in developing countries. It is endemic in Saharan and sub-Saharan Africa, the Middle East and the Indian sub-continent. The primary hosts for peste des petits ruminants virus (PPRV) are goats and sheep; however recent models studying the pathology, disease progression and viremia of PPRV have focused primarily on goat models. This study evaluates the tissue tropism and pathogenesis of PPR following experimental infection of sheep and goats using a quantitative time-course study. Upon infection with a virulent strain of PPRV, both sheep and goats developed clinical signs and lesions typical of PPR, although sheep displayed milder clinical disease compared to goats. Tissue tropism of PPRV was evaluated by real-time RT-PCR and immunohistochemistry. Lymph nodes, lymphoid tissue and digestive tract organs were the predominant sites of virus replication. The results presented in this study provide models for the comparative evaluation of PPRV pathogenesis and tissue tropism in both sheep and goats. These models are suitable for the establishment of experimental parameters necessary for the evaluation of vaccines, as well as further studies into PPRV-host interactions.

1 February 2003 in Journal of Virology
Verified
Journal Article
Open access
PDF file
ZHZiying Han
Ziying Han
HBHani Boshra
Hani Boshra
JSJ. Oriol Sunyer
J. Oriol Sunyer
SZSusan H. Zwiers
Susan H. Zwiers
JPJason Paragas
Jason Paragas
Ronald HartyRonald Harty
Ronald Harty
The VP24 protein of Ebola virus is believed to be a secondary matrix protein and minor component of virions. In contrast, the VP40 protein of Ebola virus is the primary matrix protein and the most abundant virion component. The structure and function of VP40 have been well characterized; however, virtually nothing is known regarding the structure and function of VP24. Wild-type and mutant forms of VP24 were expressed in mammalian cells to gain a better understanding of the biochemical and functional nature of this viral protein. Results from these experiments demonstrated that (i) VP24 localizes to the plasma membrane and perinuclear region in both transfected and Ebola virus-infected cells, (ii) VP24 associates strongly with lipid membranes, (iii) VP24 does not contain N-linked sugars when expressed alone in mammalian cells, (iv) VP24 can oligomerize when expressed alone in mammalian cells, (v) progressive deletions at the N terminus of VP24 resulted in a decrease in oligomer formation and a concomitant increase in the formation of high-molecular-weight aggregates, and (vi) VP24 was present in trypsin-resistant virus like particles released into the media covering VP24-transfected cells. These data indicate that VP24 possesses structural features commonly associated with viral matrix proteins and that VP24 may have a role in virus assembly and budding.

21 March 2006 in Immunogenetics
Verified
Journal Article
Closed access
PDF file
MLMarie Løvoll
Marie Løvoll
TKTerje Kilvik
Terje Kilvik
HBHani Boshra
Hani Boshra
JBJarl Bøgwald
Jarl Bøgwald
JSJ. Oriol Sunyer
J. Oriol Sunyer
Roy Ambli DalmoRoy Ambli Dalmo
Roy Ambli Dalmo